Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared Highlights from the National ICE-T Congress 2026:
1. “Kicking off ICE-T 2026 Session 1
Honored to have Dr. Saad Usmani from Memorial Sloan Kettering Cancer Center sharing insights on:
- CAR-T in Multiple Myeloma
- Clinical trial outcomes vs real-world experience
- Efficacy, durability and evolving patient selection
A powerful start to an exciting meeting!”
2. “Session 1 at ICE-T 2026 continues strong
Honored to hear Dr. Natalie Grover from UNC Lineberger Comprehensive Cancer Center discuss:
- CAR-T in Lymphoma
- Evolving standards of care
- Patient selection and sequencing in a rapidly changing landscape
Transforming outcomes in aggressive lymphomas – exciting era ahead!”
3. “Session 1 at ICE-T 2026 keeps pushing boundaries
Great talk by Felicia Cao from UNC Lineberger Comprehensive Cancer Center on:
- CAR-T in Solid Tumors
- Early clinical experience
- Challenges in tumor microenvironment and trafficking
A glimpse into the next frontier of cellular therapy.”
4. “Session 1 at ICE-T 2026 closing strong
Excellent presentation by Mike Gunwald from Atrium Health Wake Forest Baptist on:
- CAR-T and Bispecific Antibodies in ALL
- Expanding treatment landscape
- Sequencing strategies and real-world integration
Rapidly evolving space with meaningful impact on patient outcomes.”
5. “Panel discussion for session 1: Q and A
6. ” Session 2 at ICE-T 2026
Bispecific antibodies are redefining the MM landscape!
Dr. Prerna Mewawalla (Allegheny Health System) highlights the power of Teclistamab, Elranatamab and next-gen BsAbs – bringing deep responses in heavily pretreated disease with evolving safety profiles.
“Beyond BCMA” strategies on the horizon”
7. “Session 2 at ICE-T 2026
Dr. Marc Hoffmann from KU Cancer Center highlights the expanding role of bispecific antibodies in lymphoma – reshaping treatment paradigms with “off-the-shelf” immunotherapy.
- CD20xCD3 BsAbs driving high response rates in R/R disease
- Rapid deployment vs CAR-T
- CRS, infections, and sequencing remain key considerations
A major step forward in accessible cellular immunotherapy.”
8. “Session 3 at ICE-T 2026
Jessica McElwee, PharmD and Brandon Tedder, MD (Levine Cancer Institute) deliver a high-yield session on immunotherapy toxicities:
- CRS – early recognition and prompt management
- ICANS – structured neuro monitoring is key
- ICAHT / IEC-HS – emerging, underrecognized complications
Multidisciplinary approach = safer delivery of CAR-T and BsAbs”
9. “Session 3 at ICE-T 2026
Urvi Desai, MD and Alyssa MacKay, DO dive into CAR-T–related neurotoxicity (ICANS) – a critical toxicity every team must master:
- Early detection with ICE score
- Range: mild confusion – severe encephalopathy
- Timely steroids = key intervention
- Team-based monitoring is essential
Precision care = safer CAR-T delivery.”
10. “Session 3 at ICE-T 2026
Dr. Zainab Shahid from Memorial Sloan Kettering Cancer Center highlights infection prevention post–CAR-T – an essential pillar of patient care:
- Prolonged immunosuppression and hypogammaglobulinemia
- IVIG support and antimicrobial prophylaxis
- Vigilance for viral reactivation
- Long-term monitoring is key
Keeping patients safe beyond response is just as critical.”
11. “Meeting many of our speakers between sessions!”
12. “Session 4: The Debate “BiTE Vs CAR-T in myeloma at National ICE-Congress 2026
Dr. Vorhees vs Dr. McGuirk”
13. “Final Session
Keynote at ICE-T 2026
Dr. Keith M. Sullivan (Duke) shares a visionary talk on the future of cellular and bispecific therapies – expanding beyond malignancies into autoimmune diseases.
- New horizons for transplant and cell therapy
- Bridging oncology and immunology
- The next frontier is already here”
14. “Outstanding work and kudos to two exceptional leaders – Dr. Shebli Atrash and Dr. Barry Paul – for organizing an incredible National ICE-T Congress in Charlotte, NC
Truly a fantastic effort bringing innovation, collaboration, and excellence in cellular therapy to the forefront!”
15. “Big News | ICE-T Congress 2026
Get ready, Orlando!
Orlando, FL July 18, 2026
The National ICE-T Congress is back – bigger, bolder, and pushing the future of Cell Therapy forward
Led by powerhouse chairs: Megan Melody and Jose Sandoval S and our ICE-T Executive Director: Zahra M
- CAR-T
- Bispecifics
- Real-world innovation
- Multidisciplinary impact
This is where the future of hematology meets action. Don’t miss it.”
Other articles featuring Al-Ola A Abdallah on OncoDaily.
